Sarepta Therapeutics Statistics
Sarepta Therapeutics (AB3A) Stock Statistics & Valuation Metrics
Total Valuation
Sarepta Therapeutics has a market cap or net worth of EUR 1.70B. The enterprise value is EUR 2.10B.
- Market Cap
- EUR 1.70B
- Enterprise Value
- EUR 2.10B
Share Statistics
Sarepta Therapeutics has 107,235,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 107,235,850
- Owned by Insiders
- 5.99%
- Owned by Institutions
- 52.97%
Financial Efficiency
Sarepta Therapeutics’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -29.03%.
- Return on Equity (ROE)
- -0.63
- Return on Assets (ROA)
- -0.21
- Return on Invested Capital (ROIC)
- -29.03%
- Return on Capital Employed (ROCE)
- -0.29
- Revenue Per Employee
- 2.63M
- Profits Per Employee
- -854.38K
- Employee Count
- 835
- Asset Turnover
- 0.66
- Inventory Turnover
- 0.96
Valuation Ratios
The current PE Ratio of Sarepta Therapeutics is 191.56. Sarepta Therapeutics’s PEG ratio is 0.38.
- PE Ratio
- 191.56
- PS Ratio
- 0.93
- PB Ratio
- 1.19
- Price to FCF
- -57.62
- Price to Operating Cash Flow
- -106.65
- PEG Ratio
- 0.38
Income Statement
In the last 12 months, Sarepta Therapeutics had revenue of 2.20B and earned -713.41M in profits. Earnings per share was -7.13.
- Revenue
- 2.20B
- Gross Profit
- 1.32B
- Operating Income
- -657.77M
- Pretax Income
- -702.23M
- Net Income
- -713.41M
- EBITDA
- -647.97M
- Earnings Per Share (EPS)
- -7.13
Cash Flow
In the last 12 months, operating cash flow was -17.12M and capital expenditures -14.48M, giving a free cash flow of -31.60M billion.
- Operating Cash Flow
- -17.12M
- Free Cash Flow
- -31.60M
- Free Cash Flow per Share
- -0.30
Dividends & Yields
Sarepta Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.74%
- Earnings Yield
- 0.81%
Stock Price Statistics
- Beta
- 1.16
- 52-Week Price Change
- 2.40%
- 50-Day Moving Average
- 16.75
- 200-Day Moving Average
- 15.95
- Relative Strength Index (RSI)
- 53.61
- Average Volume (3m)
- 198
Important Dates
Sarepta Therapeutics upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Sarepta Therapeutics as a current ratio of 2.32, with Debt / Equity ratio of 91.16%
- Current Ratio
- 2.32
- Quick Ratio
- 1.48
- Debt to Market Cap
- 0.37
- Net Debt to EBITDA
- -0.37
- Interest Coverage Ratio
- -67.60
Taxes
In the past 12 months, Sarepta Therapeutics has paid 11.19M in taxes.
- Income Tax
- 11.19M
- Effective Tax Rate
- -0.02
Enterprise Valuation
Sarepta Therapeutics EV to EBITDA ratio is 15.47, with an EV/FCF ratio of -75.98.
- EV to Sales
- 1.23
- EV to EBITDA
- 15.47
- EV to Free Cash Flow
- -75.98
- EV to Operating Cash Flow
- -140.23
Balance Sheet
Sarepta Therapeutics has EUR 878.78M in cash and marketable securities with EUR 1.05B in debt, giving a net cash position of -EUR 174.25M billion.
- Cash & Marketable Securities
- EUR 878.78M
- Total Debt
- EUR 1.05B
- Net Cash
- -EUR 174.25M
- Net Cash Per Share
- -EUR 1.62
- Tangible Book Value Per Share
- EUR 14.15
Margins
Gross margin is 56.25%, with operating margin of -2.50%, and net profit margin of 0.75%.
- Gross Margin
- 56.25%
- Operating Margin
- -2.50%
- Pretax Margin
- 1.91%
- Net Profit Margin
- 0.75%
- EBITDA Margin
- 7.93%
- EBIT Margin
- 6.29%
Analyst Forecast
The average price target for Sarepta Therapeutics is EUR 19.19, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 19.19
- Price Target Upside
- 15.45% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 18
- Revenue Growth Forecast
- -23.76%
- EPS Growth Forecast
- 62.88%
Scores
- Smart Score
- 5
- AI Score
- ―
